Psoriasis Disease Pipeline Drugs AssessmentPosted by ahila on April 3rd, 2018 Psoriasis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 Psoriasis Disease Pipeline Drugs AssessmentOverview: Psoriasis is a genetic inflammatory diseases which affects skin. Psoriasis is characterised by skin cells that multiply up to 10 times faster than normal. When these cells reach surface and die, raised, red plaques covered with white scales for. Psoriasis begins as a small scaling papule. When multiple papules coalesce, they form scaling plaques. These plaques tend to occur in the scalp, elbows, and knees. Symptoms includes red patches on skin, small scaling spots, dry and cracked skin, burning, itching and soreness of skin, bleeding etc. Psoriasis is diagnosed by physical examination and skin biopsy. Psoriasis is treated by topical corticosteroids, Vitamin D analogues, Topical retinoid, Calcineurin inhibitors etc. and it can be treated by phototherapy A sample of this report is available upon request @
Segmentation: By Trial Phase, Psoriasis pipeline drugs are segmented as:
By Company, Psoriasis pipeline drugs are segmented as:
By Drugs, Psoriasis pipeline drugs are segmented as:
By Type of Condition, Psoriasis pipeline drugs are segmented as:
By Route of Administration, Psoriasis pipeline drugs are segmented as:
To view TOC of this report is available upon request @ Like it? Share it! More by this author |